Project Grant K99CA312800
Award Date 6/15/26
Completion Date 5/31/28
Dollars Obligated $136K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct fundamental research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas. The award, effective April 1, 2026 through March 31, 2031, supports investigation of SMARCAL1 as a synthetic lethal vulnerability in Alternative Lengthening of Telomeres (ALT)-positive...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $434,969 to the University of Pennsylvania through the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, for a five-year project period concluding April 30, 2031. The award supports fundamental research investigating the cellular mechanisms that sustain FLT3-mutant acute myeloid leukemia (AML) clone persistence during targeted kinase inhibitor therapy. The research combines genetically engineered...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $302,524 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, with completion expected by April 30, 2028. This F32 postdoctoral fellowship grant funds biomedical research training and career development in cancer research, supporting an investigator's research into the role of SMARCAL1 depletion in enhancing...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $100,228 to the University of Pennsylvania under the Cancer Research Manpower program (CFDA 93.398) to support research training and investigator development in cancer research. The award, obligated on December 1, 2026, with completion targeted for April 30, 2029, funds a research project titled "Identifying Immune Mediators in BRCA1/2 Deficient High Grade Serous Ovarian Cancer." The project delivers...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $459,902 Project Grant to the University of Pennsylvania, effective August 1, 2025 through May 31, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award provides salary support for Research Specialist Dr. Charly Good to advance Dr. Shelley Berger's National Cancer Institute-funded cancer research program investigating how wildtype and gain-of-function mutant p53 proteins regulate genes in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded the University of Pennsylvania $109,076 in Project Grant funding (Award Date: January 15, 2026; Completion Date: July 31, 2029) to support research investigating genes that limit Chimeric Antigen Receptor T (CAR T) cell persistence in solid tumors. The funded research focuses on identifying and characterizing genetic mechanisms—specifically the ATXN7L3 and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $323,860 Project Grant on August 18, 2025, to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and investigator development in cancer science. The project, titled "Investigating the Role of Mutagenic DNA Repair During the Persistence of Cancer Cells," will be conducted at the Institute's New York facility through April...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $658,722 to The Regents of the University of California, San Francisco on March 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the mechanisms of tumor cell immortality in TERT (telomerase reverse transcriptase) promoter mutant cancers. The research aims to understand how mutations in the TERT promoter activate telomerase reactivation and cellular immortality—a hallmark of...
- Project Grant Award Summary The National Cancer Institute awarded $211,112 to President and Fellows of Harvard College (operating as Harvard Medical School) on August 14, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The award, which extends through March 31, 2029, funds a research project investigating the role of Replication Protein A (RPA) in Polymerase Theta-mediated End-Joining (TMEJ), a...